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ABSTRACT
Sphingosine kinase 1 (SPHK1), an oncogenic kinase, has previously been found 
to be upregulated in various types of human malignancy and to play a crucial role 
in tumor development and progression. Although SPHK1 has gained increasing 
prominence as an important enzyme in cancer biology, its potential as a predictive 
biomarker and a therapeutic target in cervical cancer remains unknown. SPHK1 
expression was examined in 287 formalin-fixed, paraffin-embedded cervical cancer 
tissues using immunohistochemistry, and its clinical implications and prognostic 
significance were analyzed. Cervical cancer cell lines including HeLa and SiHa were 
treated with the SPHK inhibitors SKI-II or FTY720, and effects on cell survival, 
apoptosis, angiogenesis, and invasion were examined. Moreover, the effects of 
FTY720 on tumor growth were evaluated using a patient-derived xenograft (PDX) 
model of cervical cancer. Immunohistochemical analysis revealed that expression of 
SPHK1 was significantly increased in cervical cancer compared with normal tissues. 
SPHK1 expression was significantly associated with tumor size, invasion depth, FIGO 
stage, lymph node metastasis, and lymphovascular invasion. Patients with high SPHK1 
expression had lower overall survival and recurrence-free survival rates than those 
with low expression. Treatment with SPHK inhibitors significantly reduced viability 
and increased apoptosis in cervical cancer cells. Furthermore, FTY720 significantly 
decreased in vivo tumor weight in the PDX model of cervical cancer. We provide 
the first convincing evidence that SPHK1 is involved in tumor development and 
progression of cervical cancer. Our data suggest that SPHK1 might be a potential 
prognostic marker and therapeutic target for the treatment of cervical cancer.
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INTRODUCTION
Cervical cancer is one of the most common malignant 
neoplasms worldwide, and is responsible for the death of 
thousands of women every year [1, 2]. Although there is 
increasing evidence that early detection of cervical cancer 
has reduced mortality, the prognosis of advanced or recurrent 
cervical cancer remains very poor. Current treatment for 
cervical cancer, including surgery with radiation therapy, 
chemotherapy, and concurrent chemoradiation therapy, can 
yield cures in 80% to 90% of women with early stage I and 
II cervical cancer and 60% of those with stage II disease. 
In contrast, effective treatment options for advanced or 
recurrent cervical cancer are exceedingly limited. Cisplatin-
based combination chemotherapy, the most commonly 
used cytotoxic therapy [3], has yielded response rates 
ranging from 20% to 30% and overall survival of less than 
10 months in these patients [4]. Because of the minimal 
degree of success with cytotoxic therapies and the poor 
prognosis of patients, there is increased interest in targeted 
therapeutics for the management of advanced, recurrent, or 
metastatic cervical cancer.
An emerging area of investigation in lipid research has 
been the role of sphingolipids in cancer biology. Many groups 
are actively investigating the role of different sphingolipid 
enzymes, sphingolipid binding proteins, and transmembrane 
transporters in human cancers [5]. Among these, members 
of the sphingosine kinase (SPHK) family have received 
the most attention as important enzymes in cancer biology 
because their catalytic activity lies at a critical intersection in 
the regulation of bioactive sphingolipid metabolism. SPHK 
exists as two isoforms: SPHK1 and SPHK2. Sphingosine 
1-phosphate (S1P), one of the metabolites, plays a crucial 
role in intracellular and extracellular signaling [6]; SPHK1 
catalyzes the phosphorylation of sphingosine to form S1P, 
which regulates multiple cellular processes including 
inhibition of apoptosis, increased cell proliferation, and 
angiogenesis [7]. Accumulating evidence has suggested 
that SPHK1 is involved in processes associated with 
cancer progression, including cell transformation, survival, 
and migration, metastasis, and tumor microenvironment 
neovascularization [8].
SPHK1 is upregulated in human cancers of many 
different organs including head and neck [6], stomach 
[7], lung [9], brain [10, 11], colon [12, 13], and ovary 
[14]. In this regard, SPHK1 may be a suitable therapeutic 
target, and inhibitors of SPHK1 have been proposed 
as potential anticancer agents [15, 16]. For example, 
silencing the expression of SPHK1 in glioblastoma 
cells and breast cancer cells induced cell cycle arrest 
[17], and inhibition of SPHK1 dramatically decreased 
breast cancer formation [18]. Blocking SPHK1 activity 
suppressed tumor growth and reduced tumor occurrence 
and metastasis in nude mice [19, 20]. Similarly, we 
recently demonstrated that treatment with SPHK inhibitors 
significantly reduced cell proliferation, angiogenesis, 
and invasion, and increased apoptosis in ovarian cancer 
cells [16]. However, there are no available data on the 
expression of SPHK1 in cervical cancer and its biological 
and clinical significance. Furthermore, the therapeutic 
effects of SPHK inhibitors in cervical cancer remain 
unknown. The purpose of this study was to evaluate 
the clinical implications and prognostic significance of 
SPHK1 expression and to investigate the in vitro and in 
vivo effects of targeting SPHK1 with pharmacological 
inhibitors in cervical cancer.
RESULTS
Protein expression of SPHK1 in human cervical 
cancer tissues and cell lines
We examined SPHK1 protein expression in 287 
cervical cancer and 5 normal cervical tissue samples 
using immunohistochemical staining. Representative 
photomicrographs of SPHK1 immunostaining are 
shown in Figure 1A. We observed that 63.8% (183/287) 
of the cancer tissue samples showed high SPHK1 
expression and 36.2% (104/287) showed low expression. 
Immunoreactivity for SPHK1 was mainly localized in 
the cytoplasm of cancer cells, which is consistent with 
previous studies on SPHK1 expression in other types of 
human cancer [7, 10, 12, 16, 21, 22]. In contrast, none 
of the normal cervical tissue samples exhibited SPHK1 
expression. Consistent with findings from the tissue 
samples, SPHK1 protein was strongly expressed in all 
human cervical cancer cell lines examined (Figure 1B).
SPHK1 expression is significantly associated 
with aggressive oncogenic behavior of 
cervical cancer
We examined the relationship between SPHK1 
expression in cervical cancer tissue and different 
clinicopathological characteristics (Table 1). High SPHK1 
expression was associated with larger tumor size (p < 0.001), 
deeper invasion depth (p < 0.001), presence of lymph node 
metastasis (p = 0.029), higher FIGO stage (p = 0.029), 
presence of lymphovascular invasion (p = 0.045), and higher 
preoperative squamous cell carcinoma (SCC) antigen level 
(p = 0.009), indicating that SPHK1 expression is associated 
with aggressive oncogenic behavior of cervical cancer. 
However, no correlation was observed between SPHK1 
expression and age, parametrial invasion, and vaginal 
resection margin involvement.
SPHK1 expression is an independent prognostic 
factor for recurrence-free survival in patients 
with cervical cancer
Adequate clinical follow-up information was 
available for all 287 patients with cervical cancer. 
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The mean survival time for the patient cohort was 
5.55 years. Death was reported in 11 of 287 cases (3.8%), 
of which 10 (90.9%) had high SPHK1 expression. As 
shown in Table 2, univariate analysis for OS revealed that 
SPHK1 expression (p = 0.033; Figure 1C), tumor size 
(p = 0.033), and lymph node metastasis (p = 0.008) were 
associated with OS. Multivariate analysis demonstrated 
that lymph node metastasis (p = 0.033) independently 
predicted OS. Although SPHK1 expression was found to 
have the highest relative risk for death (5.643), it did not 
predict OS by itself (p = 0.101).
Recurrences were reported in 35 of 287 cases 
(12.2%), and 91.4% (32/35) of these had high SPHK1 
expression. Univariate analysis for RFS showed that 
SPHK1 expression (p = 0.008; Figure 1D), tumor 
size (p = 0.009), depth of invasion (p = 0.049), lymph 
node metastasis (p < 0.001), and lymphovascular 
invasion (p < 0.001) were significant predictors of 
Figure 1: SPHK1 overexpression in human cervical cancer and its prognostic significance. A. Immunohistochemical staining 
of SPHK1 in normal cervix and cervical cancer tissues. B. Western blot analysis of SPHK1 in cervical cancer cell lines. C and D. Kaplan-
Meier curves showing (C) OS and (D) RFS of cervical cancer patients. E to H. Kaplan-Meier curves showing (E and F) OS and (G and H) 
RFS of the patient subgroups divided according to the status of FIGO stage and lymph node metastasis.
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poor RFS (Table 2). Furthermore, in multivariate 
analysis, SPHK1 expression, lymph node metastasis, 
and lymphovascular invasion were identified as 
independent prognostic factors for RFS. This analysis 
also demonstrated that high SPHK1 expression in cervical 
cancer had the highest relative risk of recurrence (3.604), 
superior to the risk associated with lymph node metastasis 
(2.483) or lymphovascular invasion (2.716).
Moreover, we evaluated the prognostic value of 
SPHK1 expression in selected patient subgroups. We did 
not find any difference in OS when patients with high and 
low SPHK1 expression were grouped according to the FIGO 
stage (Figure 1E) or presence of lymph node metastasis 
(Figure 1F). In contrast, there were significant differences 
in RFS between the high and low SPHK1 expression groups 
for FIGO stage I (p = 0.037) and stage II (p < 0.001; Figure 
1G). In addition, there were significant differences between 
the RFS of patients with high expression and low expression 
according to the absence (p = 0.032) or presence (p = 0.003) 
of lymph node metastasis (Figure 1H). Taken together, our 
data suggest that SPHK1 is a potentially useful predictor 
for outcome of cervical cancer. In particular, we found that 
SPHK1 is a novel independent biomarker for predicting RFS 
of patients with cervical cancer.
SPHK inhibitors significantly affect cell survival 
and apoptosis in cervical cancer cells
We used two SPHK inhibitors, SKI-II and FTY720, 
to block the endogenous activity of SPHK1 in human 
cervical cancer cell lines. In both HeLa and SiHa cells, 
SKI-II significantly reduced cell viability in a dose-
dependent manner and increased apoptosis (Figure 2A). 
FTY720 inhibited cervical cancer cell survival to a greater 
degree than SKI-II in both cell lines (Figure 2B).
Effect of SPHK inhibitors on SPHK1 enzymatic 
activity and levels of MMP-2 and VEGF-A
FTY720 significantly decreased the expression of 
both matrix metalloproteinase (MMP)-2 and vascular 
endothelial growth factor (VEGF)-A in HeLa cells 
whereas SKI-II significantly reduced the expression of 
VEGF-A, but not that of MMP-2 (Figure 3A). To confirm 
the specific effects of these inhibitors on SPHK1, we 
measured SPHK1 enzymatic activity. FTY720, but not 
SKI-II, significantly repressed the enzymatic activity 
(Figure 3B).
Table 1: Relationship between SPHK1 expression and clinicopathologic characteristics
Characteristics Total SPHK1 expression p value
High Low
Age (years) ≥49 141 87 (61.7) 54 (38.3) 0.475
<49 146 96 (65.8) 50 (34.2)
Tumor size (cm) ≥4.0 132 81 (80.2) 20 (19.8) <0.001*
<4.0 155 102 (54.8) 84 (45.2)
Depth of invasion (cm) ≥1.0 159 124 (78.0) 35 (22.0) <0.001*
<1.0 128 59 (46.1) 69 (53.9)
Lymph node metastasis Present 77 57 (74.0) 20 (26.0) 0.029*
Absent 210 126 (60.0) 84 (40.0)
FIGO stage IA 15 9 (60.0) 6 (22.4) 0.029*
IB 214 129 (60.3) 85 (39.7)
II 58 45 (77.6) 13 (22.4)
Lymphovascular invasion Present 130 91 (70.0) 39 (30.0) 0.045*
Absent 157 92 (58.6) 65 (41.4)
Parametrial invasion Present 33 23 (69.7) 10 (30.3) 0.451
Absent 254 160 (63.0) 94 (37.0)
Resection margin involvement Present 14 10 (71.4) 4 (28.6) 0.777
Absent 273 173 (63.4) 100 (36.6)
Preoperative SCC (ng/mL) ≥1.5 137 98 (71.5) 39 (28.5) 0.009*
<1.5 150 85 (56.7) 65 (43.3)
*Statistically significant (p < 0.05).
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FTY720 inhibits tumor growth in 
patient-derived xenograft cervical cancer model
We developed the patient-derived xenografts 
(PDX) model by subrenal implantation of human 
cervical cancer tissues. FTY720 (10 mg/kg) was injected 
intraperitoneally into mice every 2 days starting 1 month 
after the implantation of xenograft tissues and treatment 
was continued for 4 weeks. FTY720 significantly 
inhibited tumor growth in the cervical cancer PDX 
model (Figure 4A). We also confirmed the inhibitory 
effect of FTY720 on cell proliferation (Figure 4B) and its 
proapoptotic effect (Figure 4C). Moreover, we observed 
significantly decreased SPHK1 enzymatic activity in 
harvested xenograft tissues (Figure 4D).
DISCUSSION
Consistent with previous reports [7, 11, 16, 22–24], 
this study showed that the expression of SPHK1 is 
increased in both cervical cancer cell lines and tissues. 
Of particular interest, the expression of SPHK1 was 
associated with well-known prognostic parameters 
including tumor size, invasion depth, lymph node 
metastasis, FIGO stage, and lymphovascular invasion. 
We also demonstrated that elevated expression of SPHK1 
correlates with a poor prognosis and is an independent 
prognostic factor for predicting poor RFS. These findings 
implicate SPHK1 as a potentially important contributing 
factor in cervical cancer progression. Our results are 
consistent with previous studies demonstrating an 
association between increased SPHK1 expression and 
aggressive oncogenic behaviors such as larger tumor, 
deeper invasion depth, advanced clinical stage, poorer 
pathologic differentiation, higher invasive capacity, and/or 
chemotherapeutic resistance in head and neck cancer [25], 
thyroid cancer [26], salivary duct cancer [22], esophageal 
cancer [27], colorectal cancer [28], and bladder cancer 
[29]. Furthermore, previous studies have found that 
SPHK1 overexpression is a prognostic biomarker for the 
survival of patients with glioblastoma [10], head and neck 
cancer [6], salivary duct cancer [22], esophageal cancer 
[27], gastric cancer [7], and colorectal cancer [28].
Table 2: Univariate and multivariate analyses for OS and RFS
Characteristics OS RFS
Univariate Multivariate Univariate Multivariate
p value p value RR 95% CI p value p value RR 95% CI
Age (years) ≥49 0.732 NA 0.658 NA
Tumor size (cm) ≥4.0 0.033* 0.396 1.785 0.468–6.815 0.009* 0.570 1.254 0.574–2.742
Depth of invasion 
(cm) ≥1.0 0.100 0.799 1.248
0.227–
6.852 0.049* 0.442 0.715 0.304–1.683
Lymph node 
metastasis Present 0.008* 0.033* 3.842
1.115–
13.238 <0.001* 0.013* 2.483 1.208–5.106
FIGO stage II 0.129 NA 0.128 NA
Lymphovascular 
invasion Present 0.066 0.498 1.668
0.380–
7.326 <0.001* 0.022* 2.716 1.156–6.379
Parametrial 
invasion Present 0.456 NA 0.099 0.449 1.398 0.587–3.328
Resection margin 
involvement Present 0.533 NA 0.369 NA
Preoperative SCC 
(ng/mL) ≥1.5 0.582 NA 0.063 0.677 0.848 0.392–1.838
SPHK1 expression High 0.033* 0.101 5.643 0.714–44.590 <0.001* 0.008* 3.604 1.388–9.365
Abbreviations: OS, overall survival; RFS, recurrence-free survival; RR, relative risk; CI, confidence interval; NA, not 
applicable.
*Statistically significant.
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Figure 2: Effects of SPHK inhibitors SKI-II and FTY720 on cell survival and apoptosis in HeLa and SiHa cells. Both 
A. SKI-II and B. FTY720 elicited cytotoxic effects (upper; MTT assay) and increased apoptosis (lower; FACS analysis). FTY720 exerted 
more potent inhibitory effects than SKI-II in both cell lines. The error bar represents standard error of mean. *p < 0.05, **p < 0.01.
We further demonstrated that blocking SPHK1 with 
pharmacological inhibitors significantly impaired cervical 
cancer cell survival and inhibited their proliferation. 
Moreover, treatment with FTY720 induced a significant 
reduction in tumor weight and proliferative activity and 
an increase in tumor cell apoptosis in the cervical cancer 
PDX model compared with controls. These findings 
are in agreement with our previous observations that 
inhibition of SPHK1 with FTY720 significantly reduced 
cell proliferation and increased apoptosis in ovarian 
cancer cells [16]. In addition, we showed that FTY720 
significantly decreased the intracellular enzymatic 
activity of SPHK1 and the expression level of MMP-2 
and VEGF-A, both of which are closely linked to tumor 
invasion, metastasis, and angiogenesis. These results 
provide new insights into the alterations of SPHK1 
expression and activity that are associated with the 
development and progression of cervical cancer. We 
suggest that therapeutic targeting of SPHK1 is a potential 
therapeutic strategy for the treatment of cervical cancer.
Although SPHK1 and SPHK2 catalyze the same 
biochemical reactions, these two isoforms differ in their 
substrate specificities, subcellular localization, and tissue 
distribution [5, 30]. Several studies have shown that 
SPHK2 has antiproliferative effects. In contrast to the 
prosurvival factor SPHK1, overexpression of SPHK2 
causes suppression of cell growth and cell cycle arrest 
[31]. Thus, SPHK1 and SPHK2 are not equivalent in 
their effects on biological activity despite enzymatic 
similarities. Strategies that have been applied to limit 
the effects of SPHK1-S1P signaling in cancer include 
inhibition of SPHK1 and/or SPHK2 and targeting of 
specific S1P receptors. SKI-II noncompetitively inhibits 
SPHK1 and SPHK2 activity. In contrast, FTY720, a S1P 
receptor-selective sphingosine analog, is a competitive 
inhibitor of SPHK1 [14]. In this study, FTY720 exerted 
a more potent inhibitory effect on cell survival and the 
production of MMP-2 and VEGF-A than SKI-II. It 
is possible that the antitumor effect of SKI-II via the 
inhibition of SPHK1 may be counteracted by its blocking 
effect on SPHK2, since SPHK1 and SPHK2 play opposing 
roles in the regulation of cell survival and apoptosis. 
Consequently, SKI-II is less effective than FTY720, which 
affects SPHK1 specifically.
In conclusion, we demonstrated that elevated 
expression of SPHK1 is significantly associated with 
the development and progression of cervical cancer. 
Expression of SPHK1 represents a novel and independent 
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biomarker for the prognosis of patients with cervical 
cancer. Our findings indicate that inhibition of SPHK1 
with pharmacological inhibitors results in potent antitumor 
activity in cervical cancer in vitro and in vivo. Further 
preclinical and clinical development of SPHK inhibitors, 
particularly FTY720, to treat this disease is warranted.
MATERIALS AND METHODS
Cell lines and treatment
Human cervical cancer cell lines (Ca Ski, HeLa, 
SiHa, ME-180, and MS751) were purchased from the 
American Type Culture Collection (Manassas, VA, USA). 
The cell lines were maintained in complete media (RPMI 
1640 for Ca Ski; DMEM for HeLa; MEM for SiHa and 
MS751; McCoy’s 5A for Me-180) supplemented with 
10% fetal bovine serum (FBS) and 0.1% gentamicin 
sulfate (Gemini Bio-Products, Calabasas, CA, USA) 
in 5% CO2 at 37°C. The SPHK inhibitors SKI-II 
(2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole; 
Calbiochem, Merck KGaA, Darmstadt, Germany) and 
FTY720 (Fingolimod; Cayman Chemical, Ann Arbor, 
MI, USA) were resuspended in dimethyl sulfoxide at a 
concentration of 100 μg/mL. Cells were seeded at 3 × 103 
cells/well in a 96-well microplate in culture media with 
10% FBS. Cells were treated with SPHK inhibitors as 
described in previous reports [32, 33].
Patients and tissue specimens
A total of 287 patients with uterine cervical 
cancer who received surgery at the Department of 
Obstetrics and Gynecology at Samsung Medical 
Figure 3: Effects of SPHK inhibitors SKI-II and FTY720 on levels of VEGF-A and MMP-2 and enzymatic activity of 
SPHK1 in HeLa cells. A. The level of VEGF-A (upper), assessed by ELISA (24 hr) was significantly decreased after treatment with 
FTY720 or SKI-II. In contrast, MMP-2 level was significantly reduced only after treatment with FTY720. B. Similarly, FTY720, but not 
SKI-II, significantly decreased SPHK1 enzymatic activity. The error bar represents standard error of mean. *p < 0.05, **p < 0.01.
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Center (Seoul, Republic of Korea) between January 
2002 and December 2009 were included in this study. 
Five normal uterine cervix specimens were used as 
controls. Two board-certified gynecologic pathologists 
examined the specimens using hematoxylin and eosin 
staining. Specimens in which tumor tissue accounted 
for more than 90% of the total volume were included 
in the analysis. This study was reviewed and approved 
by the Institutional Review Board at Samsung Medical 
Center (Seoul, Republic of Korea; Protocol No.: SMC # 
2012-09-045).
Western blot
Preparation of lysates from cultured cells or tumor 
tissues was performed as described previously [16, 34]. 
Protein bands were probed with a 1:1, 000 dilution of 
anti-SPHK1 antibody (Cell Signaling Technology, Inc., 
Beverly, MA, USA) or 1:3, 000 dilution of anti-β-actin 
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA), and then labeled with horseradish peroxidase-
conjugated anti-rabbit antibody (GE Healthcare, 
Piscataway, NJ, USA). Bands were visualized with an 
Figure 4: Effects of FTY720 on in vivo tumor weight, cell proliferation, apoptosis, and enzymatic activity of SPHK1 
in cervical cancer PDX models. A. In each image, normal kidney (left) and a developed xenograft tissue are shown. FTY720 resulted 
in a significantly reduced tumor weight compared with PBS-injected control. B. In the FTY720-treated group, harvested tumor tissues 
showed significantly decreased Ki-67 proliferative indices. C. A significant increase in the number of apoptotic cells in the FTY720-treated 
group was visualized by the TUNEL assay. D. SPHK1 enzymatic activity in harvested tumor tissues was significantly decreased in the 
FTY720-treated group. The error bar represents standard error of mean. *p < 0.05, **p < 0.01.
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enhanced chemiluminescence kit (Amersham Biosciences, 
Buckinghamshire, UK) according to the manufacturer’s 
protocol.
Immunohistochemistry
Immunohistochemical staining was performed on 
formalin-fixed, paraffin-embedded, 4-μm-thick tissue 
sections, using a Bond-maX automated immunostainer 
(Leica Biosystems, Melbourne, Australia) and a Bond 
Polymer Refined Detection Kit (Vision Biosystems, 
Melbourne, Australia). The primary antibodies were 
rabbit polyclonal anti-SPHK1 antibody (1:200; Cell 
Signaling Technology, Inc.) and mouse monoclonal anti-
Ki-67 antibody (1:50; clone MIB-1, Dako, Glostrup, 
Denmark). Briefly, antigen retrieval was performed at 
97°C for 20 min in ER1 or ER2 buffer. After blocking 
endogenous peroxidase activity with 3% hydrogen 
peroxide for 10 min, primary antibody incubation 
was performed for 15 min at room temperature. To 
verify antibody specificity, anti-mouse IgG (AI-2000; 
Vector Laboratories, Burlingame, CA, USA) was 
used instead of the primary antibody as a negative 
control. The degree of immunostaining of SPHK1 
was evaluated according to staining proportion and 
intensity by combining scores for the proportion 
of positively stained cancer cells and the staining 
intensity, as previously described [11, 26]. Briefly, 
the area of stained cancer cells was scored as follows: 
0, none; 1, <10%; 2, 10–50%; and 3, >50% of all cancer 
cells. The staining intensity was determined as follows: 
0, no staining; 1, weak staining; 2, moderate staining; 
and 3, strong staining. The final score was calculated 
as the product of staining proportion and intensity, 
resulting in scores of 0, 1, 2, 3, 4, 6, and 9. The optimal 
cutoff value for high and low SPHK1 expression level 
was chosen on the basis of distribution of the staining 
results and a measure of heterogeneity with the log-
rank test with respect to overall survival (OS). A final 
score ≥ 4 was used to define tumors with high SPHK1 
expression, and a final score ≤ 3 was indicated low 
SPHK1 expression.
3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay
The MTT assay was performed as previously 
described [34, 35]. Each sample was assayed in triplicate.
Apoptosis assay
Cell apoptosis was measured at 48 hr using 
the Annexin V-FITC Apoptosis Detection Kit-1 (BD 
Biosciences Pharmingen, San Diego, CA, USA) according 
to the manufacturer’s protocol. Each sample was assayed 
in triplicate.
Measurement of SPHK1 enzymatic activity
Whole cell lysates were prepared from cancer cell 
lines or tumor tissues as described previously [16]. The 
protein concentration was determined using the Bradford 
Protein Assay kit (Bio-Rad Laboratories, Inc., Hercules, 
CA, USA). Total lysate samples were assayed for SPHK1 
enzymatic activity using a commercial Sphingosine 
Kinase Activity Assay Kit (Echelon Biosciences, Salt 
Lake City, UT, USA), as previously described [26].
Enzyme-linked immunosorbent (ELISA) assay
For analysis of MMP-2 and VEGF-A secretion, 
culture media were harvested and centrifuged to remove 
cellular debris 24 hr after treatment with FTY720 or 
SKI-II. Media were concentrated by centrifugal filtration 
at 4, 000 rpm for 20 min using the Amicon Ultra-10K 
concentrator (Millipore, Billerica, MA, USA). ELISA kits 
(R&D Systems Europe, Ltd., Abingdon, UK) were used as 
described by the manufacturer to measure concentrations 
of human MMP-2 and VEGF-A. Each sample was assayed 
in triplicate.
Animal care and development of in vivo models 
using patient-derived xenografts
This study was reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) 
of the Samsung Biomedical Research Institute (Seoul, 
Republic of Korea; Protocol No.: H-A9-003), which is 
accredited by the Association for the Assessment and 
Accreditation of Laboratory Animal Care International 
and abides by the guidelines of the Institute of Laboratory 
Animal Resources. Tumor derived from a 32-year-old 
woman (Sample No. CX21) was histologically defined as 
FIGO stage IIA1 cervical cancer that exhibited parametrial 
and lymphovascular invasion. The patient received radical 
hysterectomy with pelvic lymph node dissection, followed 
by adjuvant concurrent chemotherapy and radiation 
therapy, and no recurrence was detected until 12 months 
postoperative follow-up. Female BALB/c nude mice were 
purchased from Orient Bio (Seongnam-si, Gyeonggi-do, 
Republic of Korea). For the PDX model of cervical cancer, 
surgically obtained tumor specimens were cut into small 
pieces (less than 2–3 mm) and implanted into the subrenal 
capsule of the left kidney of mice [36]; the tumor cells were 
propagated by serial transplantation. The mice used in these 
experiments were 6 to 8 weeks old. Mice (n = 10 per group) 
were monitored daily for tumor development and sacrificed 
either on day 60–70 or when any of the mice appeared 
moribund. We recorded body weight, tumor weight, and 
number of tumor nodules. Tumor tissues were fixed in 10% 
buffered formalin and embedded in paraffin, or placed in 
embedding compound (Tissue-Tek O.C.T., Sakura Finetek 
Japan, Tokyo, Japan) and snap-frozen with liquid nitrogen.
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Terminal deoxynucleotidyl transferase-mediated 
dUTP nick end labeling (TUNEL) assay
The TUNEL assay was performed as previously 
described [35] using the DeadEnd Fluorometric TUNEL 
System (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions.
Data analysis
The chi-square or Fisher’s exact test was performed 
to determine whether SPHK1 expression in cervical cancer 
was associated with clinicopathological characteristics. 
Univariate and multivariate survival analyses were used to 
examine the prognostic significance of SPHK1 expression 
in patients with cervical cancer. Curves for OS and 
recurrence-free survival (RFS) were generated according 
to the Kaplan-Meier method, and differences were 
analyzed using the log rank test for univariate analysis. 
Multivariate analysis was performed on parameters with 
p value < 0.1 in the univariate analysis using the Cox 
proportional hazards model (95% confidence interval) 
with a backward stepwise elimination method. The Mann-
Whitney U test was used to evaluate significance and 
compare differences among groups for in vitro and in vivo 
assays. p values < 0.05 were considered to be statistically 
significant. The SPSS software package (version 18.0; 
IBM SPSS, Chicago, IL, USA) was used for all statistical 
analyses.
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